The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

Include large-scale hepatectomy patients who meet the Inclusion criteria into the experimental group. Patient will be sent to ICU monitoring after surgery , the investigators will evaluate the blood routine, liver and kidney function, blood coagulation function, and immune inflammation indicators on the first day after surgery, and large veins will be temporarily indwelled within 48-72 hours Hemodialysis tube, then take artificial liver treatment which lasts 4-6h, follow-up test results on the 1st day, 3rd day, 7th day, 1 month and 3 months about blood routine, liver and kidney function, coagulation function, blood ammonia, Immune inflammation indicators, imaging examinations (CT or MR) at 7 days, 1 month and 3 months after treatment, to evaluate the recovery of liver function and liver regeneration after artificial liver treatment.

Inclusion criteria

• Diagnosed as liver cancer, hepatolithiasis, benign liver tumor, with clear indications for liver resection;
• Liver function Child A-B;
• There is no contraindication to surgery for cardiopulmonary function;
• The expected remaining liver volume/standard liver volume is less than 50%;

Exclusion criteria

• In the late stage of the disease, patients with frequent symptoms such as cerebral edema accompanied by cerebral herniation and clinical evidence indicating intracranial hemorrhage;
• PaO2/FiO2 is less than 200 and cannot be corrected;
• Patients with diffuse intravascular coagulation;
• Those with active bleeding;
• Uncontrolled infection;
• The platelet count is less than 50,000/μL and cannot be corrected;
• There is no blood vessel available for dialysis treatment;
• HIV, HDV or HCV positive;
• Drug abuse within 1 year;
• Those with severe systemic circulatory failure;
• Those who are highly allergic to the drugs used in the treatment process, such as plasma, heparin, protamine, etc.;
• Combined pregnancy;
• Patients with hepatorenal syndrome;
• Patients with autoimmune liver disease;
• Patients with non-alcoholic fatty liver and hereditary liver diseases (Wilson syndrome and a-antitrypsin deficiency);
• Other conditions that the clinician believes cannot tolerate the treatment.